Dimensional Fund Advisors
KROS icon

Dimensional Fund Advisors’s Keros Therapeutics KROS Stock Holding History

Dimensional Fund Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Buy
321,360
+263,347
+454% +$4.07M ﹤0.01% 2589
2025
Q4 		$1.18M Buy
58,013
+22,055
+61% +$387K ﹤0.01% 2840
2025
Q3 		$569K Sell
35,958
-678
-2% -$10K ﹤0.01% 2972
2025
Q2 		$489K Hold
36,636
– – ﹤0.01% 2996
2025
Q1 		$374K Sell
36,636
-118,527
-76% -$1.38M ﹤0.01% 3036
2024
Q4 		$2.46M Buy
155,163
+2,727
+2% +$142K ﹤0.01% 2736
2024
Q3 		$8.85M Sell
152,436
-9,279
-6% -$458K ﹤0.01% 2352
2024
Q2 		$7.39M Sell
161,715
-3,691
-2% -$198K ﹤0.01% 2370
2024
Q1 		$10.9M Sell
165,406
-5,446
-3% -$323K ﹤0.01% 2270
2023
Q4 		$6.79M Sell
170,852
-425
-0.2% -$13.3K ﹤0.01% 2468
2023
Q3 		$5.46M Buy
171,277
+112,511
+191% +$4.2M ﹤0.01% 2503
2023
Q2 		$2.36M Buy
+58,766
New +$2.58M ﹤0.01% 2732

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors's KROS Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Keros Therapeutics (KROS) stake by 454% in Q1 2026, buying an estimated $4.07M and bringing the position to 321,360 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Dimensional Fund Advisors first reported a position in KROS in Q2 2023 and has held it in 12 quarters since. The position peaked at $10.9M in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Dimensional Fund Advisors held 321,360 shares of Keros Therapeutics worth $3.55M as of Q1 2026.
  • Dimensional Fund Advisors bought 263,347 Keros Therapeutics shares in Q1 2026, an estimated $4.07M.
  • Keros Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2589 holding.
  • Dimensional Fund Advisors first reported a position in Keros Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Dimensional Fund Advisors's Keros Therapeutics position peaked at $10.9M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.